Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LASS6 Double Nickase Plasmid (h): sc-403901-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LASS6 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LASS6 Double Nickase Plasmid (h) and LASS6 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CERS6. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LASS6 Antibody (L-18): sc-100554
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LASS6 Double Nickase Plasmid (h) | sc-403901-NIC | 20 µg | $410.00 | |||
LASS6 Double Nickase Plasmid (h2) | sc-403901-NIC-2 | 20 µg | $410.00 |
CERS6 encodes ceramide synthase 6 (LASS6), an endoplasmic reticulum–localized enzyme that preferentially generates C16-ceramide, a central bioactive sphingolipid regulating membrane composition and signaling. By controlling ceramide abundance, LASS6 influences sphingolipid metabolism and intersects with pathways governing apoptosis, autophagy, ER stress responses, and inflammatory signaling. Altered CERS6 activity has been linked to dysregulated lipid homeostasis and phenotypes relevant to cancer cell survival and migration, metabolic stress, and neuroinflammatory processes. As a node in ceramide–sphingomyelin–glycosphingolipid interconversion, CERS6 is commonly studied to connect lipid remodeling with organelle function and stress-adaptation programs.
LASS6 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CERS6 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CERS6. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CERS6 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CERS6-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.